ConductScience.org, home

Paper41335396

Decoding the role of mesothelin in tumor dynamics and targeted treatment innovations.

Silvestri R and 4 others. Mol Biomed, 2025. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Decoding the role of mesothelin in tumor dynamics and targeted treatment innovations. Papers, record 41335396. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41335396

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Decoding the role of mesothelin in tumor dynamics and targeted treatment innovations.
PubMed
Journal
Mol Biomed
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2026-06-26
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Silvestri RRobertohttps://orcid.org/0000-0002-5588-5235
2Colucci EEmanuelahttps://orcid.org/0000-0003-3569-691X
3Piccardi MMargheritahttps://orcid.org/0000-0002-5199-4522
4Landi SStefanohttps://orcid.org/0000-0001-8364-6357
5Gemignani FFedericahttps://orcid.org/0000-0003-1297-0701

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
GPI-Linked ProteinsMajor topic
NeoplasmsMajor topic
Humans
Mesothelin
Tumor Microenvironment
Animals
Epithelial-Mesenchymal Transition
Molecular Targeted Therapy
Cancer-Associated Fibroblasts

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
Department of Excellence 2023-2027 initiativeMinistero dell'Università e della RicercaPubMed

Source PubMed

Download CSV of grants

References176

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119201924Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment.Am J Respir Crit Care Med2009https://conductscience.org/library/papers/19201924PubMed
240010770Targeting mesothelin-CD24 axis repolarizes tumor-associated macrophages to potentiate PD-1 blockade therapy in high-grade serous ovarian cancer.J Immunother Cancer2025https://conductscience.org/library/papers/40010770PubMed
326733616HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients.Clin Cancer Res2016https://conductscience.org/library/papers/26733616PubMed
431126960Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study).Clin Cancer Res2019https://conductscience.org/library/papers/31126960PubMed
528507279Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis.Oncotarget2017https://conductscience.org/library/papers/28507279PubMed
640315330Robust differentiation of NK cells from MSLN.CAR-IL-15-engineered human iPSCs with enhanced antitumor efficacy against solid tumors.Sci Adv2025https://conductscience.org/library/papers/40315330PubMed
730254313Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin - a case-control comparison nested into a prospective cohort of asbestos-exposed workers.Sci Rep2018https://conductscience.org/library/papers/30254313PubMed
837501016Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results.Nat Med2023https://conductscience.org/library/papers/37501016PubMed
925613900Proteomics. Tissue-based map of the human proteome.Science2015https://conductscience.org/library/papers/25613900PubMed
1032611684Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models.Sci Transl Med2020https://conductscience.org/library/papers/32611684PubMed
1117909009High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor dependent MCAT motif.Cancer Res2007https://conductscience.org/library/papers/17909009PubMed
1223989979A tumorigenic factor interactome connected through tumor suppressor microRNA-198 in human pancreatic cancer.Clin Cancer Res2013https://conductscience.org/library/papers/23989979PubMed
1329554494Driving CARs on the uneven road of antigen heterogeneity in solid tumors.Curr Opin Immunol2018https://conductscience.org/library/papers/29554494PubMed
1429507805Serum mesothelin and other biomarkers: what have we learned in the last decade?J Thorac Dis2018https://conductscience.org/library/papers/29507805PubMed
159935157111Indium-labeled monoclonal antibody K1: biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin.Int J Cancer1999https://conductscience.org/library/papers/9935157PubMed
1636564099
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
Int J Gynecol Cancer2023https://conductscience.org/library/papers/36564099PubMed
1737304291Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures.Front Immunol2023https://conductscience.org/library/papers/37304291PubMed
1833476708Furin is not required for processing of mesothelin precursor protein.Biochim Biophys Acta Mol Cell Res2021https://conductscience.org/library/papers/33476708PubMed
1932616712Histoepigenetic analysis of the mesothelin network within pancreatic ductal adenocarcinoma cells reveals regulation of retinoic acid receptor gamma and AKT by mesothelin.Oncogenesis2020https://conductscience.org/library/papers/32616712PubMed
2026823490Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer.Mol Cancer Ther2016https://conductscience.org/library/papers/26823490PubMed

See all 176 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42798783Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer.MedComm (2020)2026https://conductscience.org/library/papers/42798783PubMed
42149255Peptides as integrative modulators for clinical prognosis and targeted therapy in pancreatic cancer.Discov Oncol2026https://conductscience.org/library/papers/42149255PubMed
41994562Mesothelin biology and the evolving landscape of targeted immunotherapy.Mol Ther Oncol2026https://conductscience.org/library/papers/41994562PubMed
41665753Obstacles and improvement strategies for CAR-T cell therapy in solid tumors.Discov Oncol2026https://conductscience.org/library/papers/41665753PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
MMP74316PubTator's text mininghttps://conductscience.org/library/genes/4316NCBI Gene
MSLN10232PubTator's text mininghttps://conductscience.org/library/genes/10232NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41335396

GET https://conductscience.org/api/papers/v1/41335396/references?page=2